Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A trial of thioridazine in mental deficiency.

The British journal of psychiatry : the journal of mental science·1963
Same author

The outside employment of hospitalized mentally defective patients as a step towards resocialization.

American journal of mental deficiency·1955
See all related articles

Related Experiment Video

Updated: Jul 14, 2026

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet
13:09

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

Methylcellulose for obesity

J N BADHAM

    Lancet (London, England)
    |December 19, 1953
    PubMed
    Summary

    No abstract available in PubMed .

    Keywords:
    METHYLCELLULOSE/therapeutic useOBESITY/therapy

    More Related Videos

    Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
    05:18

    Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

    Published on: November 22, 2024

    An Acupoint Catgut-embedding Therapy for Treating Obesity
    04:50

    An Acupoint Catgut-embedding Therapy for Treating Obesity

    Published on: April 4, 2025

    Related Experiment Videos

    Last Updated: Jul 14, 2026

    Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet
    13:09

    Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet

    Published on: July 31, 2021

    Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
    05:18

    Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

    Published on: November 22, 2024

    An Acupoint Catgut-embedding Therapy for Treating Obesity
    04:50

    An Acupoint Catgut-embedding Therapy for Treating Obesity

    Published on: April 4, 2025